Approval · Notice of Compliance 27933 · 2022
PRIVA-DUTASTERIDE: Notice of Compliance 27933
Issued April 7, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27933
- Date
- April 7, 2022
- Company
- Nora Pharma Inc.Varennes, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Change in Product Ownership. Administrative: Licensing Agreement Between Two Companies
- Canadian reference product
- AVODART (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRIVA-DUTASTERIDE | 02490587 | Marketed |
Medicinal ingredients
- DUTASTERIDE 0.5 MG per CAP